{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:38:49Z","timestamp":1783600729291,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,22]]},"DOI":"10.7759\/cureus.45789","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T20:08:05Z","timestamp":1695413285000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Simran","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Sojitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhenelle","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwa","family":"Folawemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parikshit","family":"Bittla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivana","family":"Ramphall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_354_21","article-title":"Effect of pioglitazone on nonalcoholic fatty liver disease in morbid obese patients; a randomized controlled trial","volume":"12","author":"Sayadishahraki M","year":"2023","unstructured":"Sayadishahraki M, Mirfendereski S, Kachuei A, Rafiee Zadeh A, Mirghaderi A. Effect of pioglitazone on nonalcoholic fatty liver disease in morbid obese patients; a randomized controlled trial. Adv Biomed Res. 2023, 12:27. 10.4103\/abr.abr_354_21","journal-title":"Adv Biomed Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza S","year":"2021","unstructured":"Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front Biosci (Landmark Ed). 2021, 26:206-37. 10.2741\/4892","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison SA","year":"2022","unstructured":"Harrison SA, Manghi FP, Smith WB, et al.. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022, 28:1432-8. 10.1038\/s41591-022-01861-9","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince A","year":"2020","unstructured":"Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020, 42:101092. 10.1016\/j.molmet.2020.101092","journal-title":"Mol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha H","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al.. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021, 12:843-61. 10.1007\/s13300-021-01011-3","journal-title":"Diabetes Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi H","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, et al.. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022, 6:120-32. 10.1002\/hep4.1696","journal-title":"Hepatol Commun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:422-34. 10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda M","year":"2021","unstructured":"Yoneda M, Honda Y, Ogawa Y, et al.. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021, 9:10.1136\/bmjdrc-2020-001990","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium-glucose cotransporter\u00a02 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho KY","year":"2021","unstructured":"Cho KY, Nakamura A, Omori K, et al.. Favorable effect of sodium-glucose cotransporter\u00a02 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig. 2021, 12:1272-7. 10.1111\/jdi.13457","journal-title":"J Diabetes Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19046","article-title":"Pioglitazone for the treatment of metabolic-associated fatty liver disease in people living with HIV and prediabetes","volume":"13","author":"Kamolvisit S","year":"2021","unstructured":"Kamolvisit S, Chirnaksorn S, Nimitphong H, Sungkanuparph S. Pioglitazone for the treatment of metabolic-associated fatty liver disease in people living with HIV and prediabetes. Cureus. 2021, 13:e19046. 10.7759\/cureus.19046","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2049","article-title":"Comparison of Tofogliflozin and Glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita Y","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al.. Comparison of Tofogliflozin and Glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022, 45:2064-75. 10.2337\/dc21-2049","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.613389","article-title":"Sodium-glucose cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Euh W","year":"2021","unstructured":"Euh W, Lim S, Kim JW. Sodium-glucose cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021, 12:613389. 10.3389\/fendo.2021.613389","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson D","year":"2021","unstructured":"Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021, 17:484-95. 10.1038\/s41574-021-00507-z","journal-title":"Nat Rev Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073668","article-title":"SGLT2 inhibitors as the most promising influencers on non-alcoholic fatty liver disease outcome","volume":"23","author":"Mirarchi L","year":"2022","unstructured":"Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 inhibitors as the most promising influencers on non-alcoholic fatty liver disease outcome. Int J Mol Sci. 2022, 23:10.3390\/ijms23073668","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101049","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: state of the art on effective therapeutics based on the gold standard method for diagnosis","volume":"50","author":"Mahjoubin-Tehran M","year":"2021","unstructured":"Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A. Non-alcoholic fatty liver disease and steatohepatitis: state of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab. 2021, 50:101049. 10.1016\/j.molmet.2020.101049","journal-title":"Mol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian J","year":"2021","unstructured":"Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol (Lausanne). 2021, 12:615409. 10.3389\/fendo.2021.615409","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/180757-efficacy-of-sglt2-inhibitors-versus-pioglitazone-in-the-treatment-of-non-alcoholic-fatty-liver-disease-or-non-alcoholic-steatohepatitis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:45Z","timestamp":1707509265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/180757-efficacy-of-sglt2-inhibitors-versus-pioglitazone-in-the-treatment-of-non-alcoholic-fatty-liver-disease-or-non-alcoholic-steatohepatitis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.45789","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,22]]}}}